Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DJR
|
|||
| Former ID |
DNCL001622
|
|||
| Drug Name |
AMG 167
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8; ICD-9: 733.9] | Phase 1 | [1] | |
| Company |
Amgen Thousand
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sclerostin (SOST) | Target Info | Modulator | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TWEAK Signaling Pathway | |||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01101048) An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density. U.S. National Institutes of Health. | |||
| REF 2 | Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.